The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

The FDA and the maker of the popular diabetes and weight loss drug Ozempic are warning people not to use counterfeit semaglutide 1.0 milligrams — the Ozempic injection — found in the U.S. drug supply ...

BMO Capital Markets analyst Evan Seigerman said Pfizer’s discontinuation of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early stages of ...

The failure of Pfizer Inc.’s obesity pill, its highest profile experimental drug, raises the odds that the drugmaker will ...

Mounjaro, a once-weekly injection approved by India's drug regulator, is priced at 4,375 rupees ($50.86) for a 5 milligram ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

Pfizer had intended to move the drug into late-stage testing, but called it quits after a patient in a clinical trial experienced a potentially drug-related liver injury. View on euronews ...